Ken Griffin Rapt Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$1.76 - $3.75 $93,456 - $199,125	-53,100 Reduced 67.47%	25,600 $51,000
Q2 2024 Aug 14, 2024	SELL	$2.89 - $9.38 $9,248 - $30,016	-3,200 Reduced 3.91%	78,700 $240,000
Q1 2024 May 15, 2024	SELL	$6.87 - $26.45 $1.39 Million - $5.37 Million	-202,900 Reduced 71.24%	81,900 $735,000
Q4 2023 Feb 14, 2024	BUY	$11.28 - $25.46 $179,352 - $404,814	15,900 Added 5.91%	284,800 $7.08 Million
Q3 2023 Nov 14, 2023	BUY	$16.34 - $24.66 $151,962 - $229,338	9,300 Added 3.58%	268,900 $4.47 Million
Q2 2023 Aug 14, 2023	SELL	$16.06 - $21.61 $52,997 - $71,313	-3,300 Reduced 1.26%	259,600 $4.85 Million
Q1 2023 May 15, 2023	SELL	$17.19 - $30.8 $2.37 Million - $4.24 Million	-137,800 Reduced 34.39%	262,900 $4.82 Million
Q4 2022 Feb 14, 2023	BUY	$16.28 - $24.6 $81,400 - $123,000	5,000 Added 1.26%	400,700 $7.93 Million
Q3 2022 Nov 14, 2022	BUY	$17.96 - $30.46 $28,736 - $48,736	1,600 Added 0.41%	395,700 $9.52 Million

104

27.1M

26.7K

2.4K

Ticker RAPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,656,600
Market Cap $36.5M
Description
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.